Brind.

89bio is developing therapies for MASH, and the company's operations are subject to the requirements of Nasdaq Listing Rule 5635(c).

1 report, 1 independent Updated Sep 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

89bio is developing therapies for MASH, and the company's operations are subject to the requirements of Nasdaq Listing Rule 5635(c).

Who's involved

What this event is mainly about
89bioMash

Keep exploring

The entities involved

  • 89bio

    Nothing else this week.

  • Mash

    Japanese singer-songwriter

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswire89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopha